Abstract Introduction Heart failure with preserved ejection fraction (HFpEF) now accounts for nearly half of heart‑failure admissions and carries a grim prognosis, yet clinicians lack quick, low‑cost tools for early risk stratification. Emerging evidence implicates systemic, low‑grade inflammation—captured by blood‑cell ratios—in HFpEF pathobiology. Method We performed a retrospective cohort study using the publicly available MIMIC-IV database. Adults (≥18 y) with HFpEF were identified by ICD-9/10 codes and a documented left-ventricular ejection fraction ≥ 50%. NLPR was calculated as (neutrophils ÷ lymphocytes) × platelets. The primary endpoint was 28-day all-cause mortality. Univariate and multivariable logistic regression and Kaplan-Meier survival curves assessed the association between NLPR and mortality. Result Among 871 eligible patients (median age 74 y; 55% men), 43 (4.9 %) died within 28 days. Median NLPR was markedly higher in non-survivors than survivors (6.06 vs 2.15). An NLPR cut-off of 5.0 optimally discriminated risk (sensitivity 82.2 %, specificity 62.9 %; AUC 0.73). Each one-unit rise in NLPR independently increased 28-day mortality odds by 4 % (adjusted OR 1.04, 95 % CI 1.01–1.08; p = 0.031). Patients with NLPR ≥ 5.0 had significantly lower 28-day survival (log-rank p < 0.0001). NLPR retained predictive value for 90-, 180- and 365-day mortality, though discrimination declined over time. Conclusion Elevated NLPR is an independent, readily available predictor of short-term mortality in HFpEF. Incorporating NLPR into routine assessment could improve early risk stratification and guide intensified monitoring or anti-inflammatory therapies. Prospective, multicentre validation is warranted.
No takes yet. Share an insight, caveat, or question.
Hourani et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: